Skip Navigation

AIDSInfo-at-a-glance

Issue No. 34 | August 10, 2007
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

FDA Approves Maraviroc, First Drug in New Class of Anti-HIV Medications

On August 6, 2007, the United States Food and Drug Administration (FDA) approved maraviroc (Selzentry), the first drug to be approved in the CCR5 coreceptor antagonist class of anti-HIV medications. Maraviroc has been approved for use in conjunction with other antiretrovirals in treatment-experienced adults who have exclusively CCR5-tropic HIV virus, evidence of viral replication, and resistance to multiple antiretroviral medications.

More information about maraviroc and related topics is also available:

  • FDA: Official maraviroc approval press release
  • AIDSinfo: Drug database featuring an updated maraviroc drug record and information on other approved and investigational entry and fusion inhibitors  
  • AIDSinfo: HIV Life Cycle fact sheet 
  • ClinicalTrials.gov: Clinical trials involving maraviroc
  • PubMed: Journal articles on maraviroc

AIDSinfo Launches Audio Drug Name Pronunciations

In response to requests for pronunciations of anti-HIV drug names, the AIDSinfo drug database can now tell visitors how to say the name of a drug! Simply click on the speaker icon next to the name of any drug in the database to hear it pronounced.

AIDSinfo: Drug Database

 

 

 

 

 

 

 

 

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image